Diabetic Macular Edema

The company’s lead ophthalmology candidate, EXN407, has the potential to be the first topical treatment for DR/DME.

This was a 52-week, double-masked, phase 3 randomized clinical trial in which treatment-naive adults and adults who had previously received anti-VEGF therapy for DME were included.

Marco A. Zarbin, MD, spoke with the Ophthalmology Times team about conducting a post-hoc analysis of the YOSEMITE and RHINE clinical trials and presenting the results at this year's American Academy of Ophthalmology meeting.

Mathew MacCumber, MD, PhD, FASRS, spoke with Modern Retina about his presentation at the recent Retina Society meeting in New York City titled, "0.19 mg Fluocinolone Acetonide (FAc) Implant Improves Vision and Treatment Burden in Patients with Diabetic Macular Edema: The PALADIN Study."

Diana Do, MD, spoke with the Ophthalmology Times team about her presentation of the results for the 96-week PHOTON study of aflibercept at this year's American Academy of Ophthalmology meeting.

In the clinical trial, Oxurion’s novel PKal Inhibitor, THR-149, did not meet its primary endpoint.

Biocon’s YESAFILI is intended for treatment of a number of ocular conditions, including neovascular AMD, visual impairment due to myopic choroidal neovascularisation, visual impairment due to DME and visual impairment due to macular edema secondary to retinal vein occlusion.

EURETINA 2023 highlighted important DME and DR research and data from across the globe.

The endorsement follows FDA approval in the United States this summer.

Kodiak paused further development of tarcocimab last summer after its GLEAM and GLIMMER studies in diabetic macular edema did not meet their primary endpoint.

Arshad M. Khanani, MD, MA, FASRS, highlights the fluid resolution with faricimab and the need for loading doses, especially in high-needs switch patients with nAMD or DME.

Arshad M. Khanani, MD, MA, FASRS, discusses rapid improvement with faricimab in several anatomic parameters in treatment-naïve and previously treated patients with nAMD and DME in the TRUCKEE and TAHOE studies.

Researchers are addressing growing concern over vision loss in people taking semaglutideat the American Academy of Ophthalmology annual meeting in San Francisco.

The Phase 3 DIAMOND trial of OCS-01 in Diabetic Macular Edema (DME) presents encouraging results, meeting primary and secondary endpoints.

Few injections lowers treatment burden and maintains safety profile.

Results from expert surveys provide snapshots of our understanding of DME and shed light on where the 0.19-mg FAc implant stands in the current standard of care.

A panel of retina specialists review new and emerging treatments in neovascular AMD and DME, highlighting high-dose aflibercept and KSI-301. Which emerging treatments are you most interested in?

In recent panel discussions, leaders in the retina space shared their thoughts around AMD and DME. These key quotes showcase the heart of these discussions.

A panel of retina experts discussed the challenges presented in the management of DME. Which do you think is the biggest of these challenges?

In this key role, Weil will lead the organization to commercial readiness from designing launch strategies for the US and globally.

A new survey shows that 95% of adults at risk for certain retinal diseases know a little or nothing about them. Allen hopes her story will help raise awareness and encourage those at risk to regularly prioritize their eye health.

According to the company, 4D-150 comprises its customized and evolved intravitreal vector, R100, and a transgene cassette that expresses both aflibercept and a VEGF-C inhibitory RNAi.

According to Regeneron, the approval was based on data in the PULSAR and PHOTON trials, in which the drug demonstrated clinically equivalent vision gains to aflibercept Injection 2 mg that were maintained with fewer injections.

OSC-01 is a novel, high concentration preservative-free topical OPTIREACH formulation of dexamethasone.

Aleksandra Rachiskaya, MD, a member of the Modern Retina advisory board, spoke with our team about time to fluid control with faricimab arms complete compared to aflibercept in recent studies at the 2023 ASRS annual meeting.